The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 88 (high attention) · dilution pressure elevated · listing risk high · governance risk low · runway 6.4 mo · strongest signal: Exchange deficiency notice (Sep 14, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway 6–12 months) coexists with live selling machinery (shelf filed). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 21, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-09-21 (accepted 17:00 ET) filing | 22 |
| Sep 18, 2026 | ▼ Shelf filed | S-3 filed 2026-09-18 filing | 31 |
| Sep 18, 2026 | ▼ Shelf filed | S-1 filed 2026-09-18 filing | 31 |
| Sep 14, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-09-14 (accepted 08:55 ET) filing | 48 |
| Sep 14, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-09-14 filing | 48 |
| Sep 14, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-09-14 filing | 47 |
| Sep 4, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-09-04 (accepted 16:05 ET) filing | 25 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 21,446,213 (2026-05-18) -> 28,263,733 (2026-08-12), +32% filing | 35 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $3,596,234 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 28 |
| Jun 30, 2026 | ▼ Runway 6–12 months | ~6.4 months runway: liquidity $3,689,000 as of 2026-06-30, burn $6,880,250/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 24 |
SDST Stardust Power Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · SNTI Senti Biosciences Holdings, · GCTK Glucotrack, Inc. · SOAR Volato Group, Inc. · screener →